Clinical Trial Update: Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™ [Phase 2]

View source ↗

Summary

Phase 2 trial comparing immunogenicity, safety, and reactogenicity of Tritanrix™-HepB/Hib2.5 versus Tritanrix™-HepB/Hiberix™ in Haemophilus influenzae type b va…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• Tritanrix-HepB/Hiberix
• Tritanrix™-HepB/Hib2.5

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b | Phase 2 | Status: COMPLETED